IMP 761

Drug Profile

IMP 761

Alternative Names: IMP761

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Prima BioMed
  • Developer Immutep Limited
  • Class Monoclonal antibodies
  • Mechanism of Action CD223 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 28 Nov 2017 Prima BioMed changed its name to Immutep Limited
  • 07 Jul 2017 Preclinical trials in Autoimmune disorders in Australia (unspecified route) (Prima Biomed pipeline, July 2017)
  • 02 Jan 2017 IMP 761 is available for licensing as of 02 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top